Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia

Journal of Cellular and Molecular Medicine

Volumn 15, Issue 6, 2011, Pages 1239-1253

  Carreau, Aude ^a   Hafny Rahbi, Bouchra El ^a   Matejuk, Agata ^b   Grillon, Catherine ^a   Kieda, Claudine ^a  

^a CENTRE DE BIOPHYSIQUE MOLÉCULAIRE   (France)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Hypoxia; Normoxia; Oxygen; Oxygen partial pressure; Physioxia

Indexed keywords

BIOLOGICAL MARKER; NITROIMIDAZOLE DERIVATIVE; OXYGEN;

ANIMAL; ANOXIA; ARTICLE; BLOOD; CELL HYPOXIA; DRUG EFFECT; ERYTHROCYTE; HUMAN; MAMMAL; METABOLISM; MOLECULAR IMAGING; MOLECULAR LIBRARY; NEOPLASM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PHYSIOLOGY; POLAROGRAPHY; POSITRON EMISSION TOMOGRAPHY; PRESSURE;

ANIMALS; ANOXIA; BIOLOGICAL MARKERS; CELL HYPOXIA; ERYTHROCYTES; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MAMMALS; MOLECULAR IMAGING; NEOPLASMS; NITROIMIDAZOLES; OXYGEN; PARTIAL PRESSURE; POLAROGRAPHY; POSITRON-EMISSION TOMOGRAPHY; SMALL MOLECULE LIBRARIES;

MAMMALIA;

EID: 79957635293     PISSN: 15821838     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1582-4934.2011.01258.x     Document Type: Article

References (92)

1. Vaupel P, Höckel M, Mayer A. Detection and characterization of tumor hypoxia using pO2 histography. Antioxid Redox Signal. 2007; 9: 1221-5.
2. Maeda K, Osato T, Umezawa H. A new antibiotic, azomycin. J Antibiot. 1953; 6: 182.
3. Nunn A, Linder K, Strauss HW. Nitroimidazoles and imaging hypoxia. Eur J Nucl Med. 1995; 22: 265-80.
4. Kizaka-Kondoh S, Konse-Nagasawa H. Significance of nitroimidazole compounds and hypoxia-inducible factor-1 for imaging tumor hypoxia. Cancer Science. 2009; 100: 1366-73.
5. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002; 2: 683-93.
6. Jensen RL. Brain tumor hypoxia: tumorigenesis, angiogenesis, imaging, pseudoprogression, and as a therapeutic target. J Neurooncol. 2009; 92: 317-35.
7. Holland JP, Lewis JS, Dehdashti F. Assessing tumor hypoxia by positron emission tomography with Cu-ATSM. Q J Nucl Med Mol Imaging. 2009; 53: 193-200.
8. Ter-Pogossian MM, Herscovitch P. Radioactive oxygen-15 in the study of cerebral blood flow, blood volume, and oxygen metabolism. Semin Nucl Med. 1985; 15: 377-94.
9. Boushel R, Piantadosi CA. Near-infrared spectroscopy for monitoring muscle oxygenation. Acta Physiol Scand. 2000; 168: 615-22.
10. Intes X, Chance B. Non-PET functional imaging techniques: optical. Radiol Clin North Am. 2005; 43: 221-34, xii.
11. Boushel R, Langberg H, Olesen J, et al Monitoring tissue oxygen availability with near infrared spectroscopy (NIRS) in health and disease. Scand J Med Sci Sports. 2001; 11: 213-22.
12. Busse LJ, Pratt RG, Thomas SR. Deconvolution of chemical shift spectra in two- or three-dimensional [19F] MR imaging. J Comput Assist Tomogr. 1988; 12: 824-35.
13. Mason RP, Antich PP, Babcock EE, et al Non-invasive determination of tumor oxygen tension and local variation with growth. Int J Radiat Oncol Biol Phys. 1994; 29: 95-103.
14. Zhao D, Ran S, Constantinescu A, et al Tumor oxygen dynamics: correlation of in vivo MRI with histological findings. Neoplasia. 2003; 5: 308-18.
15. Howe FA, Robinson SP, McIntyre DJ, et al Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumours. NMR Biomed. 2001; 14: 497-506.
16. Taylor JS, Tofts PS, Port R, et al MR imaging of tumor microcirculation: promise for the new millennium. J Magn Reson Imaging. 1999; 10: 903-7.
17. Baudelet C, Gallez B. How does blood oxygen level-dependent (BOLD) contrast correlate with oxygen partial pressure (pO2) inside tumors? Magn Reson Med. 2002; 48: 980-6.
18. Swartz HM. Using EPR to measure a critical but often unmeasured component of oxidative damage: oxygen. Antioxid Redox Signal. 2004; 6: 677-86.
19. Swartz HM, Walczak T. Developing in vivoEPR oximetry for clinical use. Adv Exp Med Biol. 1998; 454: 243-52.
20. Stone HB, Brown JM, Phillips TL, et al Oxygen in human tumors: correlations between methods of measurement and response to therapy. Summary of a workshop held November 19-20, 1992, at the National Cancer Institute, Bethesda, Maryland. Radiat Res. 1993; 136: 422-34.
21. Clark LC. Monitor and Control of Blood and Tissue Oxygen Tensions. ASAIO J. 1958; 2: 41-8.
22. Lübbers DW, Baumgärtl H, Zimelka W. Heterogeneity and stability of local PO2 distribution within the brain tissue. Adv Exp Med Biol. 1994; 345: 567-74.
23. Nozue M, Lee I, Yuan F, et al Interlaboratory variation in oxygen tension measurement by Eppendorf "histograph" and comparison with hypoxic marker. J Surg Oncol. 1997; 66: 30-8.
24. Vanderkooi JM, Maniara G, Green TJ, et al An optical method for measurement of dioxygen concentration based upon quenching of phosphorescence. J Biol Chem. 1987; 262: 5476-82.
25. Griffiths JR, Robinson SP. The OxyLite: a fibre-optic oxygen sensor. Br J Radiol. 1999; 72: 627-30.
26. Seylaz J, Pinard E, Meric P, et al Local cerebral PO2, PCO2, and blood flow measurements by mass spectrometry. Am J Physiol. 1983; 245: H513-8.
27. Ndubuizu O, LaManna JC. Brain tissue oxygen concentration measurements. Antioxid Redox Signal. 2007; 9: 1207-19.
28. Höckel M, Vaupel P. Biological consequences of tumor hypoxia. Semin Oncol. 2001; 28: 36-41.
29. Lawrentschuk N, Poon AMT, Foo SS, et al Assessing regional hypoxia in human renal tumours using 18F-fluoromisonidazole positron emission tomography. BJU Int. 2005; 96: 540-6.
30. Aquino-Parsons C, Luo C, Vikse CM, et al Comparison between the comet assay and the oxygen microelectrode for measurement of tumor hypoxia. Radiother Oncol. 1999; 51: 179-85.
31. Trédan O, Galmarini CM, Patel K, et al Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst. 2007; 99: 1441-54.
32. Ledoux S, Yang R, Friedlander G, et al Glucose depletion enhances P-glycoprotein expression in hepatoma cells. Cancer Res. 2003; 63: 7284-90.
33. Graeber TG, Osmanian C, Jacks T, et al Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature. 1996; 379: 88-91.
34. Kondo A, Safaei R, Mishima M, et al Hypoxia-induced enrichment and mutagenesis of cells that have lost DNA mismatch repair. Cancer Res. 2001; 61: 7603-7.
35. Gray MD, Mann M, Nitiss JL, et al Activation of the unfolded protein response is necessary and sufficient for reducing topoisomerase IIα protein levels and decreasing sensitivity to topoisomerase-targeted drugs. Molecular Pharmacology. 2005; 68: 1699-707.
36. Tannock IF. The relation between cell proliferation and the vascular system in a transplanted mouse mammary tumour. Br J Cancer. 1968; 22: 258-73.
37. Brown JM. Clinical trials of radiosensitizers: what should we expect? Int J Radiat Oncol Biol Phys. 1984; 10: 425-9.
38. Zeman EM, Brown JM, Lemmon MJ, et al SR-4233: a new bioreductive agent with high selective toxicity for hypoxic mammalian cells. Int J Radiat Oncol Biol Phys. 1986; 12: 1239-42.
39. Peters KB, Brown JM. Tirapazamine: a hypoxia-activated topoisomerase II poison. Cancer Res. 2002; 62: 5248-53.
40. von Pawel J, von Roemeling R, Gatzemeier U, et al Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors. J Clin Oncol. 2000; 18: 1351-9.
41. Williamson SK, Crowley JJ, Lara PN, et al Phase III trial of paclitaxel plus carboplatin with or without tirapazamine in advanced non-small-cell lung cancer: Southwest Oncology Group Trial S0003. J Clin Oncol. 2005; 23: 9097-104.
42. Patterson LH. Bioreductively activated antitumor N-oxides: the case of AQ4N, a unique approach to hypoxia-activated cancer chemotherapy. Drug Metab Rev. 2002; 34: 581-92.
43. Fylaktakidou KC, Lehn J, Greferath R, et al Inositol tripyrophosphate: a new membrane permeant allosteric effector of haemoglobin. Bioorg Med Chem Lett. 2005; 15: 1605-8.
44. Kieda C, Greferath R, Crola da Silva C, et al Suppression of hypoxia-induced HIF-1alpha and of angiogenesis in endothelial cells by myo-inositol trispyrophosphate-treated erythrocytes. Proc Natl Acad Sci USA. 2006; 103: 15576-81.
45. Biolo A, Greferath R, Siwik DA, et al Enhanced exercise capacity in mice with severe heart failure treated with an allosteric effector of hemoglobin, myo-inositol trispyrophosphate. Proc Natl Acad Sci USA. 2009; 106: 1926-9.
46. Ching L, Cao Z, Kieda C, et al Induction of endothelial cell apoptosis by the antivascular agent 5, 6-Dimethylxanthenone-4-acetic acid. Br J Cancer. 2002; 86: 1937-42.
47. Brauer R, Wang LS, Woon S, et al Preferential labelling of oxidisable proteins with a photoactivatable analogue of the anti-tumor agent DMXAA and evidence for redox signalling in its mode of action. Neoplasia. 2010; 12: 755-65.
48. Baader E, Tschank G, Baringhaus KH, et al Inhibition of prolyl 4-hydroxylase by oxalyl amino acid derivatives in vitro, in isolated microsomes and in embryonic chicken tissues. Biochem J. 1994; 300: 525-30.
49. Ivan M, Haberberger T, Gervasi DC, et al Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proc Natl Acad Sci USA. 2002; 99: 13459-64.
50. Wang GL, Semenza GL. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood. 1993; 82: 3610-5.
51. Gleadle JM, Ebert BL, Firth JD, et al Regulation of angiogenic growth factor expression by hypoxia, transition metals, and chelating agents. Am J Physiol Cell Physiol. 1995; 268: C1362-8.
52. Schofield CJ, Ratcliffe PJ. Oxygen sensing by HIF hydroxylases. Nat Rev Mol Cell Biol. 2004; 5: 343-54.
53. Assad F, Scultheiss R, Leniger-Follert E, et al Measurement of local oxygen partial pressure (PO2) of the brain cortex in cases of tumors. Adv Neurosurg. 1984; 12: 263-6.
54. Meixensberger J, Dings J, Kuhnigk H, et al Studies of tissue PO2 in normal and pathological human brain cortex. Acta Neurochir Suppl. 1993; 59: 58-63.
55. Hoffman WE, Charbel FT, Edelman G. Brain tissue oxygen, carbon dioxide, and pH in neurosurgical patients at risk for ischemia. Anesth Analg. 1996; 82: 582-6.
56. Dings J, Meixensberger J, Jäger A, et al Clinical experience with 118 brain tissue oxygen partial pressure catheter probes. Neurosurgery. 1998; 43: 1082-95.
57. Le Q, Chen E, Salim A, et al An evaluation of tumor oxygenation and gene expression in patients with early stage non-small cell lung cancers. Clin Cancer Res. 2006; 12: 1507-14.
58. Wang W, Winlove CP, Michel CC. Oxygen partial pressure in outer layers of skin of human finger nail folds. J Physiol. 2003; 549: 855-63.
59. Thermann M, Jostarndt L, Eberhard F, et al [Oxygen supply of the human small intestine in mechanical ileus]. Langenbecks Arch Chir. 1985; 363: 179-84.
60. Müller M, Schück R, Erkens U, et al Effects of lumbar peridural anesthesia on tissue pO2 of the large intestine in man. Anasthesiol Intensivmed Notfallmed Schmerzther. 1995; 30: 108-10.
61. Müller M, Schindler E, Roth S, et al Effects of desflurane and isoflurane on intestinal tissue oxygen pressure during colorectal surgery. Anaesthesia. 2002; 57: 110-5.
62. Leary TS, Klinck JR, Hayman G, et al Measurement of liver tissue oxygenation after orthotopic liver transplantation using a multiparameter sensor. A pilot study. Anaesthesia. 2002; 57: 1128-33.
63. Brooks AJ, Eastwood J, Beckingham IJ, et al Liver tissue partial pressure of oxygen and carbon dioxide during partial hepatectomy. Br J Anaesth. 2004; 92: 735-7.
64. Brooks AJ, Hammond JS, Girling K, et al The effect of hepatic vascular inflow occlusion on liver tissue pH, carbon dioxide, and oxygen partial pressures: defining the optimal clamp/release regime for intermittent portal clamping. J Surg Res. 2007; 141: 247-51.
65. Brezis M, Rosen S. Hypoxia of the renal medulla - its implications for disease. N Engl J Med. 1995; 332: 647-55.
66. Müller M, Padberg W, Schindler E, et al Renocortical tissue oxygen pressure measurements in patients undergoing living donor kidney transplantation. Anesth Analg. 1998; 87: 474-6.
67. Bylund-Fellenius AC, Walker PM, Elander A, et al Energy metabolism in relation to oxygen partial pressure in human skeletal muscle during exercise. Biochem J. 1981; 200: 247-55.
68. Beerthuizen GI, Goris RJ, Kreuzer FJ. Skeletal muscle Po2 during imminent shock. Arch Emerg Med. 1989; 6: 172-82.
69. Boekstegers P, Riessen R, Seyde W. Oxygen partial pressure distribution within skeletal muscle: indicator of whole body oxygen delivery in patients? Adv Exp Med Biol. 1990; 277: 507-14.
70. Ikossi DG, Knudson MM, Morabito DJ, et al Continuous muscle tissue oxygenation in critically injured patients: a prospective observational study. J Trauma. 2006; 61: 780-90.
71. 2 and blood flow in the human skeletal muscle. Arch Orthop Trauma Surg. 1988; 107: 114-6.
72. Richardson RS, Duteil S, Wary C, et al Human skeletal muscle intracellular oxygenation: the impact of ambient oxygen availability. J Physiol. 2006; 571: 415-24.
73. Guyton A. Textbook of medical physiology. 6th ed. Philadelphia: Saunders; 1981.
74. Ishikawa Y, Ito T. Kinetics of hemopoietic stem cells in a hypoxic culture. Eur J Haematol. 1988; 40: 126-9.
75. Harrison JS, Rameshwar P, Chang V, et al Oxygen saturation in the bone marrow of healthy volunteers. Blood. 2002; 99: 394.
76. Fiegl M, Samudio I, Clise-Dwyer K, et al CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure. Blood. 2009; 113: 1504-12.
77. Skouby AR. Haematologic adaptation in patients with chronic bronchitis and pulmonary insufficiency. Acta Med Scand. 1976; 199: 185-90.
78. Gluckman E, Broxmeyer HA, Auerbach AD, et al Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling. N Engl J Med. 1989; 321: 1174-8.
79. Wiesener MS, Jürgensen JS, Rosenberger C, et al Widespread hypoxia-inducible expression of HIF-2alpha in distinct cell populations of different organs. FASEB J. 2003; 17: 271-3.
80. Löfstedt T, Fredlund E, Holmquist-Mengelbier L, et al Hypoxia inducible factor-2alpha in cancer. Cell Cycle. 2007; 6: 919-26.
81. Ben-Shoshan J, Maysel-Auslender S, Luboshits G, et al Hypoxia-inducible factor-1alpha and -2alpha additively promote endothelial vasculogenic properties. J Vasc Res. 2009; 46: 299-310.
82. Ambros V. MicroRNA pathways in flies and worms: growth, death, fat, stress, and timing. Cell. 2003; 113: 673-6.
83. Suárez Y, Sessa WC. MicroRNAs as novel regulators of angiogenesis. Circ Res. 2009; 104: 442-54.
84. Kulshreshtha R, Ferracin M, Wojcik SE, et al A microRNA signature of hypoxia. Mol Cell Biol. 2007; 27: 1859-67.
85. Hebert C, Norris K, Scheper MA, et al High mobility group A2 is a target for miRNA-98 in head and neck squamous cell carcinoma. Mol Cancer. 2007; 6: 5-15.
86. Kulshreshtha R, Davuluri RV, Calin GA, et al A microRNA component of the hypoxic response. Cell Death Differ. 2008; 15: 667-71.
87. Mousa SA. Cell adhesion molecules: potential therapeutic & diagnostic implications. Mol Biotechnol. 2008; 38: 33-40.
88. Juliano RL. Signal transduction by cell adhesion receptors and the cytoskeleton: functions of integrins, cadherins, selectins, and immunoglobulin-superfamily members. Annu Rev Pharmacol Toxicol. 2002; 42: 283-323.
89. Carreau A, Kieda C, Grillon C. Nitric oxide modulates the expression of endothelial cell adhesion molecules involved in angiogenesis and leukocyte recruitment. Exp Cell Res. 2011; 317: 29-41.
90. Gao X, Xu Z. Mechanisms of action of angiogenin. Acta Biochim Biophys Sin. 2008; 40: 619-24.
91. Korsic M, Jugović D, Kremzar B. Intracranial pressure and biochemical indicators of brain damage: follow-up study. Croat Med J. 2006; 47: 246-52.
92. Gleadle J, Ratcliffe PJ. Hypoxia. In: Encyclopedia of life sciences. Chichester: John Wiley & Sons, Ltd.; 2001.